| Symbol | RVVTF |
|---|---|
| Name | REVIVE THERAPEUTICS LTD. |
| Sector | UNDEFINED |
| Region | North America |
| Industry | - |
| Address | M5C 1P1 Canada ON 82 Richmond Street East |
| Telephone | +1 888-901-0036 |
| Fax | — |
| — | |
| Website | http://www.revivethera.com |
| Incorporation | CA |
| Incorporated On | 2012 |
| Employees | — |
| Fiscal Year | 6/30 |
| Public Since | — |
| Exchanges | OTC |
| Auditor | Clearhouse LLP; |
| Audit Status | AUDITED |
| Reporting Status | International Reporting: Canadian Securities Exchange |
| CIK | — |
| Description | Revive Therapeutics is a life sciences company focused on the research and development of therapeutics and diagnostics for infectious diseases and rare disorders, and it is prioritizing drug development efforts to take advantage of several regulatory incentives awarded by the FDA such as Emergency Use Authorization, Orphan Drug, Fast Track, and Breakthrough Therapy designations. Currently, the Company is exploring the use of Bucillamine for the potential treatment of public health medical emergencies and rare inflammatory disorders. Revive is also advancing the development of Psilocybin-based therapeutics through various programs. Additional info from OTC: |
Revive Therapeutics Provides Update of Key Nerve Agent Countermeasure Study
Read moreRevive Therapeutics Provides Update of Key Nerve Agent Countermeasure Study
Read moreRevive Therapeutics Announces Closing of Second Tranche of Private Placement
Read moreRevive Therapeutics Announces Closing of First Tranche of Private Placement and Debt Settlement
Read moreRevive Therapeutics Announces Proposed Private Placement and Debt Settlement
Read moreRevive Therapeutics Clarifies Completion of Key Nerve Agent Countermeasure Study
Read moreRevive Therapeutics Nears Completion of Key Nerve Agent Countermeasure Study with Canadian Department of National Defence Highlighting Significant Stockpiling Opportunity
Read moreRevive Therapeutics Advances with Next-Generation Bucillamine Development
Read moreRevive Therapeutics Provides Update on Research Study Evaluating Bucillamine for Nerve Agent Exposure
Read more